{"id":1068289,"date":"2023-03-23T00:21:51","date_gmt":"2023-03-23T04:21:51","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/macrogenics-earns-15-million-milestone-following-u-s-fda-approval-of-zynyz-retifanlimab-dlwr\/"},"modified":"2024-08-18T11:45:25","modified_gmt":"2024-08-18T15:45:25","slug":"macrogenics-earns-15-million-milestone-following-u-s-fda-approval-of-zynyz-retifanlimab-dlwr","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/macrogenics-earns-15-million-milestone-following-u-s-fda-approval-of-zynyz-retifanlimab-dlwr.php","title":{"rendered":"MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ\u2122 (retifanlimab-dlwr)"},"content":{"rendered":"<p><![CDATA[ROCKVILLE, MD, March  22, 2023  (GLOBE NEWSWIRE) -- \u00a0MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administration\u2019s (FDA) approval of Incyte\u2019s Biologics License Application (BLA) for ZYNYZ\u2122 (retifanlimab-dlwr), the Company will receive a $15 million milestone payment from Incyte. ZYNYZ, a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), was previously developed by MacroGenics and licensed to Incyte pursuant to an exclusive global collaboration and license agreement in October 2017.]]><\/p>\n<p>Read the rest here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2023\/03\/22\/2632605\/0\/en\/MacroGenics-Earns-15-Million-Milestone-Following-U-S-FDA-Approval-of-ZYNYZ-retifanlimab-dlwr.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ\u2122 (retifanlimab-dlwr)\">MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ\u2122 (retifanlimab-dlwr)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read the rest here: MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ\u2122 (retifanlimab-dlwr) <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/macrogenics-earns-15-million-milestone-following-u-s-fda-approval-of-zynyz-retifanlimab-dlwr.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068289","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068289"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068289"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068289\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}